Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 21, 2005; 11(47): 7391-7400
Published online Dec 21, 2005. doi: 10.3748/wjg.v11.i47.7391
Published online Dec 21, 2005. doi: 10.3748/wjg.v11.i47.7391
Chronic viral hepatitis B, C, D |
Toxins (e.g., alcohol, aflatoxins) |
Hereditary metabolic liver diseases (e.g., hereditary hemochromatosis, |
α-1-antitrypsin deficiency) |
Autoimmune hepatitis |
Overweight, especially in males, and diabetes mellitus; nonalcoholic |
steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD) |
Tumor mass | <50% of liver | ≥50% of liver |
Ascites | No | Yes |
Albumin (g/L) | >3 | ≤3 |
Bilirubin (mg/dL) | <3 | ≥3 |
Points | 0 | 1 |
Stage I | 0 points | |
Stage II | 1-2 points | |
Stage III | 3-4 points |
5-Fluorouracil |
Capecitabine |
Doxorubicin |
Epirubicin |
Etoposide |
Cisplatin |
Gemcitabine |
Mitoxantrone |
Interferon alpha |
Megestrol acetate |
Tamoxifen |
Octreotide |
Thalidomide |
Thymophysin |
α-1-thymosin |
- Citation: Blum HE. Hepatocellular carcinoma: Therapy and prevention. World J Gastroenterol 2005; 11(47): 7391-7400
- URL: https://www.wjgnet.com/1007-9327/full/v11/i47/7391.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i47.7391